Agennix Incorporated
Records under this name other than patents Agennix Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,080,559 | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus Term ended Term ended Jun 29, 2018 · From the USPTO record | Term ended | Term ended Jun 29, 2018 | From the USPTO record |
| US 7,026,295 | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease Lapsed on the fee record Ended Apr 11, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 11, 2018 | From the USPTO record |
| US 7,638,487 | Lactoferrin in the reduction of pain Lapsed on the fee record Ended Dec 29, 2017 · From the USPTO record | Lapsed on the fee record | Ended Dec 29, 2017 | From the USPTO record |
| US 7,592,306 | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease Lapsed on the fee record Ended Sep 22, 2017 · From the USPTO record | Lapsed on the fee record | Ended Sep 22, 2017 | From the USPTO record |
| US 6,111,081 | Lactoferrin variants and uses thereof Formerly held Term ended Term ended May 30, 2017 · From the USPTO record | Term ended | Term ended May 30, 2017 | From the USPTO record |
| US 7,524,814 | Lactoferrin compositions and methods of wound treatment Lapsed on the fee record Ended Apr 28, 2017 · From the USPTO record | Lapsed on the fee record | Ended Apr 28, 2017 | From the USPTO record |
| US 7,420,033 | Composition of lactoferrin related peptides and uses thereof Lapsed on the fee record Ended Sep 2, 2016 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2016 | From the USPTO record |
| US 8,247,373 | Lactoferrin compositions and methods of wound treatment Lapsed on the fee record Ended Aug 21, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 21, 2016 | From the USPTO record |
| US 8,242,079 | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases Lapsed on the fee record Ended Aug 14, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 14, 2016 | From the USPTO record |
| US 8,105,615 | Lactoferrin as an adjuvant in cancer vaccines Lapsed on the fee record Ended Jan 31, 2016 · From the USPTO record | Lapsed on the fee record | Ended Jan 31, 2016 | From the USPTO record |